Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Syncona Shs GBP ( (GB:SYNC) ) has issued an announcement.
Syncona Ltd’s portfolio company, Spur Therapeutics, announced positive results from its Phase I/II GALILEO-1 study of FLT201, a gene therapy candidate for Gaucher disease. The trial demonstrated significant improvements in patients’ conditions, including reductions in glucosylsphingosine levels and sustained improvements in blood counts and organ volumes, while maintaining a favorable safety profile. These promising results, presented at the WORLDSymposium, highlight FLT201’s potential to become a first-class gene therapy for Gaucher disease, paving the way for accelerated approval and a pivotal Phase III trial in 2027, marking a significant milestone for Syncona.
More about Syncona Shs GBP
Syncona Ltd is a leading life science investor that focuses on creating, building, and scaling a portfolio of global leaders in the life sciences sector. The company aims to deliver transformational treatments to patients by investing in areas of high unmet need and building sustainable life science companies.
YTD Price Performance: -9.94%
Average Trading Volume: 687,989
Technical Sentiment Consensus Rating: Buy
For detailed information about SYNC stock, go to TipRanks’ Stock Analysis page.
